High TRA2B expression mediated by ncRNA correlates with adverse outcomes and tumor immune infiltration in...

Hepatocellular carcinoma (HCC) is one of the most frequent diagnosed malignancies globally with dismalprognosis and high mortality. Transformer 2 beta homolog (TRA2B), known as serine/arginine-rich splicing factor 10 (SRSF10), is a member of the serine/arginine (SR) protein superfamily that modulates gene expression by regulating mRNA splicing. The significance of TRA2B in cancer has received considerable attention in recent years, however, its specific role and molecular mechanisms in HCC remain unknown. This study aimed to analyze the expression of TRA2B in LIHC with the support of integrative bioinformatic analysis. The study conducted Kaplan-Meier and cox regression analyses and showed that the upregulated TRA2B was notably correlated with the dismal prognosis in HCC. TRA2B was identified as a potential proto-oncogene in HCC associated with poor prognosis. TRA2B expression in tumor tissues was found to be elevated using bioinformatics analysis. Following that, non-coding RNAs (ncRNA) related to TRA2B were extracted using series analysis. The CRNDE/LINC00511-miR-29c-3p axis was characterized as a potential upstream ncRNA-correlated signaling of TRA2B in HCC. Subsequently, the role of TRA2B in the tumor immune microenvironment (TIME) was investigated. In summary, this research provides novel insight into the potential role of TRA2B across various cancers and indicated that ncRNA-mediated overexpression of TRA2B is associated with the dismal prognosis in HCC.